Article Details

Biogen Seeks Return To Spinraza Growth As Competitors Also Pursue Dosing Advantages

Retrieved on: 2025-02-13 23:18:07

Tags for this article:

Click the tags to see associated articles and topics

Biogen Seeks Return To Spinraza Growth As Competitors Also Pursue Dosing Advantages. View article details on hiswai:

Excerpt

... Roche's Evrysdi was just approved in a new tablet formulation. Spinraza sales remain below Roche's Evrsydi, but Biogen is eyeing growth (Shutterstock).

Article found on: insights.citeline.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo